Company Announcement
COPENHAGEN, Denmark; September 12, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,356 shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:
830 shares at DKK 1,025.00,
644 shares at DKK 1,032.00,
500 shares at DKK 1,136.00,
4,658 shares at DKK 1,145.00,
311 shares at DKK 1,147.50,
100 shares at DKK 1,155.00,
130 shares at DKK 1,161.00,
1,020 shares at DKK 1,334.50,
699 shares at DKK 1,362.50,
114 shares at DKK 1,424.00,
1,111 shares at DKK 1,615.00, and
239 shares at DKK 1,948.00.
Proceeds to the company are approximately DKK 12.8 million. The increase corresponds to approximately 0.02% of the company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No. 41 of January 13, 2023, it is hereby announced that the total nominal value of Genmab A/S' share capital after the capital increase is 66,067,481 which is made up of 66,067,481 shares of a nominal value of DKK 1 each, corresponding to 66,067,481 votes.
About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO™) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.